

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 31/19, A23L 1/30		A1	(11) International Publication Number: WO 97/19683 (43) International Publication Date: 5 June 1997 (05.06.97)
(21) International Application Number: PCT/EP96/05184 (22) International Filing Date: 23 November 1996 (23.11.96) (30) Priority Data: 195 44 310.1 28 November 1995 (28.11.95) DE		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i>	
(71) Applicant (for all designated States except US): B. BRAUN MELSUNGEN AG [DE/DE]; Carl-Braun-Strasse 1, D-34212 Melsungen (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): PSCHERER, German [DE/DE]; Thüringer Strasse 32, D-34212 Melsungen (DE). JUNGINGER, Marco [DE/DE]; Himmelsbergstrasse 18, D-34212 Melsungen (DE). NEHNE, Jörg [DE/DE]; Weserring 7, D-34302 Guxhagen (DE). CARPENTIER, Yvon, A. [BE/BE]; 410, rue de Perche, B-1180 Brüssel (BE). (74) Agent: WEBER, Thomas; Postfach 10 22 41, D-50462 Köln (DE).			

(54) Title: HYDROLYSIS-OPTIMIZED LIPID EMULSIONS AND USE THEREOF

(57) Abstract

The present invention pertains to hydrolysis-optimized isotonic lipid emulsions comprising medium-chain triglycerides (MCT), vegetable oils and fish oil, as well as their use for parenteral nutrition.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Hydrolysis-Optimized Lipid Emulsions and Use Thereof

The present invention pertains to hydrolysis-optimized isotonic
10 lipid emulsions (fat emulsions) for parenteral administration,
in particular for parenteral nutrition, and their use in
situations of exaggerated inflammatory response (e.g. post-
surgery, post-trauma, sepsis, inflammatory or wasting diseases)
15 or of increased risk of vascular thrombosis and severe cardiac
arrhythmia where it is important to avoid inflicting an exogenous
triglyceride accumulation while making free fatty acids available
to different tissues of the body as rapidly as possible.

Lipid emulsions for parenteral nutrition serve to supply the body
20 with fats in an intravenously acceptable dosage form when normal
(oral) nutrition is impossible, compromised or medically
contraindicated or when it is necessary to promptly modify the
fatty acid pattern of the cells. The lipid emulsions currently
25 available are prepared from vegetable oils (e.g. safflower or
soybean oils); in some cases they also contain medium-chain
triglycerides (MCT) and/or oils of marine origin (fish oils).

Long-chain triglycerides of vegetable or marine origin serve as
an energy source and, when containing polyunsaturated fatty
30 acids, as suppliers of essential fatty acids. The classification
of such polyunsaturated fatty acids into omega-6 or omega-3
series types is based on chemical structural features, more
precisely, on the distance of the first unsaturated bond from the
methyl end (omega end) of the fatty acid molecule.

The vegetable oils, e.g. of soybean and safflower, are characterized
by a high content of polyunsaturated fatty acids of the

- 2 -

omega-6 series (predominantly linoleic acid, 18:2 n-6) whereas their content of omega-3 fatty acids (almost exclusively in the form of α -linolenic acid, 18:3 n-3) is low.

5 Fish oils obtained from cold-water fish are characterized by a high content of polyunsaturated fatty acids of the omega-3 series (predominantly eicosapentaenic acid, EPA, 20:5 n-3, and docosahexaenic acid, DHA, 22:6 n-3) whereas their content of omega-6 fatty acids is low.

10

The medium-chain triglycerides administered with the lipid emulsions serve mainly as a source of energy. Medium-chain triglycerides do not contain any unsaturated fatty acids and hence contain neither omega-6 nor omega-3 essential fatty acids.

15

Numerous clinical observations underline the principal suitability of lipid emulsions for parenteral nutrition and for substituting essential fatty acids in severe diseases and the metabolic conditions involved.

20

The human body is itself incapable of producing the vital, polyunsaturated long-chain fatty acids of the omega-6 or omega-3 series; i.e. they have to be administered orally, enterally or parenterally. The body is only able to synthesize longer-chain 25 unsaturated fatty acids from shorter-chain ones; formation of omega-6 fatty acids from precursors of the omega-3 series or vice versa is impossible, however.

30

Correspondingly, there is a need for lipid emulsions for parenteral administration which contain medium-chain triglycerides as well as triglycerides of omega-6 and omega-3 fatty acids as lipid components.

35

EP-A-0 311 091 describes isotonic lipid emulsions for parenteral nutrition comprising, in addition to conventional additives and auxiliary agents, omega-3 fatty acids, omega-3 fatty acids in the form of their esters or as components of fish oils, medium-chain

- 3 -

triglycerides, as well as optionally at least one vegetable oil providing omega-6 fatty acids in a proportion of up to 30%, based on the lipid content of the emulsion.

5 DE-OS-37 21 137 describes lipid emulsions for parenteral nutrition comprising eicosapentaenic acid triglyceride and/or docosahexaenic acid triglyceride, or fish oils containing such triglycerides, as well as vegetable oils containing omega-6 fatty acids, and medium-chain triglycerides.

10 DE-OS-34 09 793 describes a lipid emulsion for transfusion comprising a fatty acid containing from 20 to 22 carbon atoms, esters thereof, or a mixture of 2 or more of such fatty acids or esters, as well as a vegetable oil, an emulsifier, and water.

15 Said fatty acids are fatty acids from esters of marine origin (fish oils), in particular omega-3 fatty acids. Said vegetable oils are purified soybean and/or safflower oils.

20 In order that the exogenous free fatty acids are made available to the body, they must either be released hydrolytically from the infused triglycerides by means of the enzyme lipoprotein lipase (LPL) or be taken up together with emulsion particles or their remnants directly into the cells. This initial step of lipid-hydrolysis has long been considered the rate-determining step of 25 lipid metabolism. This limitation arises from the relatively limited activity of lipoprotein lipase in cleaving triglycerides. Thus, the maximum metabolizing rate for vegetable oil emulsions is about 3.8 g of lipid/kg body weight per day (Hallberg et al., Acta Physiol. Scand., Vol. 65, Suppl. 254 (1965), p. 2-23).

30 During triglyceride infusion, it is desirable to achieve triglyceride serum concentrations which are as low as possible, e.g. corresponding to a low load of the reticulo-endothelial system (RES) by exogenous lipid.

35 Typically, post-operative and post-traumatic conditions as well as severe septic episodes are characterized by a substantial

- 4 -

stimulation of the immune system. The immune response involves the release of cytokines (e.g. tumour necrosis factor and interleukins) which, at high levels, may cause severe tissue damage. In addition, high cytokine concentrations also impair hydrolysis 5 of circulating triglycerides by LPL.

In such clinical conditions, it is of particular importance to use exogenous triglycerides which are rapidly hydrolyzed and eliminated and which contain fatty acids (e.g. omega-3 fatty 10 acids) capable of reducing cytokine production as well as cytokine toxicity on tissues.

Fatty acids as an energy substrate (for oxidative purposes) and for incorporation in membranes (for structural purposes) and as 15 precursors of eicosanoids should also be made available to the body as quickly as possible.

Triglycerides typical of fish oils are hydrolyzed much more slowly than triglycerides from vegetable oils (e.g. soybean oil) 20 which are themselves hydrolyzed more slowly than medium-chain triglycerides. Addition of a fish oil emulsion to a long-chain triglyceride emulsion can even inhibit hydrolysis of long-chain triglycerides (e.g. from soybean oil) by LPL.

25 Therefore, it is an object of the invention to provide a lipid emulsion for parenteral nutrition capable of being parenterally administered which has been optimized with respect to hydrolysis and elimination, which means that the triglycerides supplied with said lipid emulsion are hydrolyzed in the body extra- or 30 intracellularly, i.e. cleaved to free fatty acids and glycerol, as quickly as possible without concomitant excessive increase of the serum level of free fatty acids. This implies that more lipids can be administered to the body parenterally within the same period of time without an increase of lipid concentration 35 or concentration of hydrolysis products.

- 5 -

This object has been achieved by a hydrolysis-optimized isotonic aqueous lipid emulsion for parenteral administration comprising, based on the total lipid content of the lipid emulsion:

- from 30% to 60% by weight of medium-chain triglycerides;
- from 35% to 65% by weight of at least one vegetable oil comprising triglycerides which supply omega-6 fatty acids;
- from 5% to 20% by weight of at least one fish oil comprising triglycerides which supply omega-3 fatty acids; and
- conventional auxiliary agents and/or additives.

Surprisingly, it has been found that the object of the invention may be achieved by combining in the same emulsion particle medium-chain triglycerides, vegetable oils rich in omega-6 fatty acids, and fish oils containing omega-3 fatty acids in the quantitative proportion mentioned above. In particular, it has been found that the MCT/vegetable oil/fish oil mixtures of the invention are more quickly hydrolyzed than known MCT/vegetable oil mixtures and MCT/vegetable oil/fish oil mixtures of the prior art. Thus, triglyceride load of the body by exogenous triglycerides is avoided. Medium-chain fatty acids and long-chain essential fatty acids become quickly available to the body. This involves no significant increase of the serum concentration of free fatty acids despite the fact that more lipids are supplied to the body per unit of time. Further, rapid incorporation of omega-3 fatty acids in platelet and leucocyte membrane phospholipids can be observed.

The lipid emulsions according to the invention include emulsified mixtures of oils (lipids) rather than mixtures of the emulsions.

According to the invention, those medium-chain triglycerides are used which have chain lengths of fatty acid ranging from C₆ to C₁₄ and which are comprised of at least 90% by weight of triglycerides of caprylic acid (C₈) and capric acid (C₁₀). The fraction of

- 6 -

medium-chain triglycerides, based on the total lipid content of the lipid emulsion, is preferably from 45% to 55%, more preferably from 48% to 52%, by weight.

5 The lipid emulsions according to the invention further contain at least one vegetable oil containing triglycerides made predominantly of omega-6 fatty acids.

10 Preferred vegetable oils are safflower oil and/or soybean oil, the content of such vegetable oils in the lipid emulsion preferably being from 35% to 45%, more preferably from 38% to 42%, by weight, based on the lipid content of the lipid emulsion. The vegetable oils contain triglycerides of fatty acids having chain lengths of C₁₆ to C₂₀ and predominantly contain triglycerides of omega-6 fatty acids.

15 Fish oils are known to contain eicosapentaenic acid (EPA, 20:5 n-3) and docosahexaenic acid (DHA, 22:6 n-3) incorporated in triglycerides which, being so-called highly unsaturated omega-3 fatty acids, are essential building blocks which have to be supplied to the body and which are biologically important, for example, as precursors of eicosanoids and as structural elements of membrane lipids. These acids are further attributed antithrombotic and lipid-lowering actions. Since their isolation from 20 natural products and their chemical synthesis is expensive, fish oils, being relatively inexpensive, are the suppliers of choice for such essential fatty acids. As used in the invention, the term "fish oils" is intended to comprise natural fish oils, processed fish oils, or highly purified fish oil concentrates.

25 According to the invention, processed fish oils may also be used, such as described e.g. in EP-A-0 298 293 which is incorporated herein by reference.

30 Suitable exemplary fish oils are oils which are obtained from cold water fish on a technically significant scale or oils which are synthetically obtainable by esterification of omega-3-fatty acids (obtained from fish oil of cold water fish, preferably

- 7 -

salmon, sardine, mackerel, herring, anchovy, smelt and swordfish, by hydrolysis of the triglycerides and subsequent purification and concentration of the resultant omega-3-fatty acids) with glycerol. Fish oils generally contain triglycerides of fatty acids having chain lengths of from 12 to 22 carbon atoms. Particularly preferred are highly purified fish oil concentrates which are obtained, for instance, from sardine, salmon, herring and/or mackerel oils. They have an eicosapentaenic acid content of from 20 to 40%, preferably at least 25%, based on the fatty acid methyl esters of the fish oil concentrate as determined by gas chromatography (percent by area). Furthermore, they have a docosahexaenic acid content of from 10 to 20%, preferably at least 12%, based on the fatty acid methyl esters of the fish oil concentrate as determined by gas chromatography (percent by area). In case of the fish oils which are synthetically obtainable by the re-esterification of the omega-3-fatty acids the total concentration of eicosapentaenic + docosahexaenic acid can be at least 45% on basis of the triglycerides.

It is particularly preferred to use a fish oil rich in EPA when inflammatory processes are to be influenced. Fish oil rich in DHA is particularly preferred in pediatric patients in the case of omega-3 fatty acid deficiency to influence growth and maturation of the central nervous system.

25 Preferably, the content of fish oil, based on the total lipid content of the lipid emulsion, is from 10% to 20%, more preferably from 10% to 14%, by weight.

30 The total lipid content of the lipid emulsion is from 5% to 30%, preferably from 10% to 25%, by weight, based on the aqueous lipid emulsion.

In addition to distilled water, the isotonic lipid emulsion contains the usual auxiliary agents and/or additives, such as emulsifiers, emulsifying aids (co-emulsifiers), stabilizers, antioxidants, and isotonizing additives.

As emulsifiers, physiologically acceptable emulsifiers are used, such as phospholipids of animal or vegetable origin. Particularly preferred are purified lecithins, especially soybean lecithin, egg lecithin, or fractions thereof, or the corresponding 5 phosphatides. The emulsifier content is from 0.6% to 1.5%, preferably 1.2%, by weight, based on the total emulsion.

Further, alkali metal salts of long-chain, C_{16} to C_{20} , fatty acids may be used as emulsifying aids (co-emulsifiers). Especially 10 preferred are their sodium salts. The co-emulsifiers are employed in concentrations of from 0.005% to 0.1%, preferably 0.02% to 0.04%, by weight, based on the total emulsion. Further, cholesterol or a cholesterol ester alone or in combination with other 15 co-emulsifiers may be employed in a concentration of from 0.005% to 0.1%, preferably from 0.02% to 0.04%, by weight.

The lipid emulsion according to the invention may contain vitamin E, in particular α -tocopherol, and/or ascorbyl palmitate as 20 antioxidants and thus for protection from peroxide formation in amounts of from 10 to 1000 mg, preferably 25 to 200 mg, based on 100 g of lipid.

For stabilization and isotonization, the emulsion according to 25 the invention may contain from 2% to 5% by weight of a stabilizing or isotonizing additive, for example, a polyhydric alcohol. In this connection, glycerol, sorbitol, xylitol or glucose are preferred, glycerol being particularly preferred.

The lipid emulsions according to the invention are invariably 30 oil-in-water (o/w) emulsions in which the outer, continuous phase consists of distilled water purified for parenteral purposes. Such o/w emulsion is obtained by mixing MCT, vegetable oil and fish oil and subsequent emulsification. After sterilization, the lipid emulsion has a pH of from 6.0 to 9.0, preferably from 6.5 35 to 8.5.

- 9 -

The isotonic lipid emulsions according to the invention can be prepared by known procedures with inertization. The usual approach is first to mix the lipids, emulsifier and other auxiliary agents and additives and then to fill up with water 5 with dispersing. The water may optionally contain additional water-soluble components (e.g. glycerol). The emulsion thus obtained still contains lipid particles having a diameter of about 10 μm . The average droplet size of the emulsion must then further be reduced by additional homogenization, e.g. using a 10 high-pressure homogenizer. For parenteral application, medium lipid droplet sizes of less than 1.0 μm , in particular less than 0.5 μm , are preferred.

The lipid emulsions according to the invention are used for 15 parenteral administration, in particular parenteral nutrition, of patients with exaggerated inflammatory responses or increased risk of vascular thrombosis or severe cardiac arrhythmia. In particular, the lipid emulsions according to the invention can be used with patients in post-operative and post-traumatic 20 conditions or inflammatory diseases; further, e.g., in severe or persistent post-aggression metabolism following operations, such as abdominal operations or organ transplantations, and multiple trauma, inflammatory diseases, burns, infections, impending or manifest sepsis, impaired respiratory function, conditions of 25 excessive production of cytokines, wasting diseases, and increased risk of severe cardiac arrhythmia (e.g. ventricular fibrillation) or vascular thrombosis. The lipid emulsion according to the invention can also be used for parenteral nutrition following shock conditions for improving microperfusion 30 and metabolic performance of organs poorly supplied with blood in terms of metabolic reanimation.

The invention will be illustrated by the following examples.

- 10 -

Preparative examples

Table 1 shows the fatty acid composition (approx. %) of various oils used in the lipid emulsions of the following examples:

- 11 -

Table 1

Fatty acid	MCT oil ¹⁾	Soybean oil ²⁾	Safflower oil ³⁾	Fish oil ⁴⁾
6:0	< 2	--	--	--
8:0	64	--	--	--
5 10:0	34	--	--	--
12:0	< 3	--	--	< 1
14:0	< 1	--	--	5
16:0	--	11	7	10
16:1	--	--	--	7
10 16:2	--	--	--	1
16:3	--	--	--	1
16:4	--	--	--	3
18:0	--	4	3	1
18:1	--	22	14	10
15 18:2 n-6	--	55	75	2
18:3 n-3	--	8	< 1	1
18:4 n-3	--	--	--	4
20:0	--	< 1	< 1	--
20:1	--	< 1	< 1	2
20: 20:4 n-6	--	--	--	2
20:5 n-3	--	--	--	28
22:1	--	--	--	1
22:4	--	--	--	< 1
22:5	--	--	--	3
25 22:6 n-3	--	--	--	13
Σ n-6	--	55	75	4
Σ n-3	--	8	< 1	46
n-6:n-3	--	7:1	$\geq 75:1$	1:12

30 ¹⁾ medium chain triglycerides, e.g. Captex 355, commercial product of Karlshamns.

²⁾ soybean oil, e.g. Sojaöl, commercial product of Croda.

³⁾ safflower oil, e.g. Safloröl, commercial product of Gustav Heess.

35 ⁴⁾ highly purified fish oil, e.g. Sanomega S28GA, commercial product of Nippon Oil and Fats.

- 12 -

Mixture I containing MCT, vegetable oil, fish oil, emulsifier (fractionated phospholipids from chicken egg yolk) is dispersed by means of Ultra-Turrax and filled up with aqueous component II with stirring. The pH value is adjusted to pH 8.0 to 9.0 using 5 an aqueous sodium hydroxide solution and/or sodium oleate. Subsequent homogenization is performed in a high-pressure homogenizer at 400 kg/cm². After dispensing in glass bottles of appropriate grade, heat sterilization is performed by known methods.

- 13 -

Table 2

Preparative Example	1 (comparative example 1*)	2	3	4	5 (comparative example 2**)
I.	medium-chain triglycerides from partial synthesis	1000 g	500 g	1000 g	1000 g
	purified safflower oil	--	--	800 g	--
	purified soybean oil	1000 g	400 g	--	800 g
	highly purified fish oil	--	100 g	200 g	200 g
	cholesterol acetate	--	--	2 g	--
	purified phospholipids from: egg	120 g egg	90 g egg	120 g egg	120 g egg
	α -tocopherol	2000 mg	1000 mg	2000 mg	2000 mg
	ascorbyl palmitate	1500 mg	--	1000 mg	1500 mg
	sodium oleate	3,0 g	2,5 g	--	3,0 g
II.	glycerol	250 g	250 g	250 g	250 g
	NaOH	--	--	to pH 8.0-9.0	--
	water for injections	ad 10 l	ad 10 l	ad 10 l	ad 10 l

5

* MCT/vegetable oil (50:50)

** MCT/vegetable oil/fish oil (50:30:20) according to EP-A-0 311 091

10 A sterile and pyrogen-free, stable emulsion resulted containing lipid droplets having an average size of less than 0.5 μ m with a shelf-life at room temperature of at least 18 months.

Example 1 (in vivo)

15

1. Determination of Triglyceride Hydrolysis

Eight male subjects (age (av. \pm st.d.) 23 \pm 3 years) were infused

with a lipid emulsion of MCT/vegetable oil (50:50) over 5 h each

20 on 4 successive days (treatment A, table 3; preparative example

- 14 -

1 in table 2). After an interval of four weeks, a lipid emulsion of MCT/vegetable oil/fish oil (50:40:10) was infused under the same conditions (treatment B, table 4; preparative example 4 in table 2). After another interval of at least eight weeks, a lipid emulsion of MCT/vegetable oil/fish oil (50:30:20) was infused under the same conditions (treatment C, table 5; preparative example 5 in table 2). Triglyceride hydrolysis in the serum (measured as the average infusion rate in mg of lipids/kg body weight/h under triglyceride clamp conditions at a serum concentration of 3.0 mmol/l from 3rd to 5th hours of infusion, 9 measurements per subject and per day; analysis of variance) was determined as follows:

Table 3

15 Treatment A (Comparative Example 1)

Average infusion rate (3rd to 5th hour) with an MCT/vegetable oil (50:50) emulsion [mg of lipids/kg body weight/h]

Subject	Day 1	Day 2	Day 3
1.	171	155	180
2.	98	103	101
3.	142	161	122
4.	180	175	166
5.	182	223	243
6.	203	259	269
7.	129	129	143
8.	188	221	170
average ± st.d.	162 ± 35	178 ± 53	174 ± 57

- 15 -

Table 4

Treatment B (according to the invention)

Average infusion rate (3rd to 5th hour) with an MCT/vegetable oil/fish oil (50:40:10) emulsion [mg of lipids/kg bodyweight/h]

5	Subject	Day 1	Day 2	Day 3
	1.	224	236	203
	2.	201	134	163
	3.	186	199	182
	4.	190	201	179
10	5.	255	278	273
	6.	259	272	271
	7.	147	154	142
	8.	176	182	181
	average ± st.d.	205 ± 39	207 ± 52	199 ± 48

15

- 16 -

Table 5

Treatment C (Comparative Example 2)

Average infusion rate (3rd to 5th hour) with an MCT/vegetable oil/fish oil (50:30:20) emulsion [mg of lipids/kg body weight/h]

5	Subject	Day 1	Day 2	Day 3
1.	202	192	186	
2.	133	122	120	
3.	147	148	174	
4.	228	211	204	
10	5.	233	241	231
6.	168	250	259	
7.	147	189	161	
8.	174	177	188	
15	average \pm st.d.	179 \pm 36	191 \pm 41	190 \pm 40

Triglyceride hydrolysis under treatment B according to the invention was significantly higher than that under treatments A ($p < 0.0001$) and C ($p < 0.05$) for all days of treatment. Thus, 20 the average infusion rate over three days was 4.9 g of triglycerides/kg body weight/day for the lipid emulsion of MCT/vegetable oil/fish oil (50:40:10), and 4.1 and 4.5 g of triglycerides/kg body weight/day, respectively, for the lipid emulsions of MCT/vegetable oil (50:50) and MCT/vegetable oil/fish oil (50:30:20). 25 The lipid emulsions composed according to preparative examples 2 and 3 give similar results. The result of a more rapid hydrolyzation of the lipid emulsions according to the invention to give free fatty acids as compared to the conventional lipid emulsions of the prior art can also be confirmed by in vitro 30 studies (cf. example 2).

- 17 -

2. Determination of the level of free fatty acids in the serum

The level of free fatty acids in the serum of the subjects was determined on the days of treatment before (0 h) and immediately following (5 h) administration of the lipid emulsion. A suitable test for this purpose is, for instance, NEFAC test (an in vitro enzymatic colorimetric method) of Wako Chemicals GmbH, Germany.

It has been found that upon administration of the lipid emulsion of MCT/vegetable oil/fish oil (50:40:10) according to the invention the serum concentrations of free fatty acids are not increased to markedly higher values as compared to administration of a commercial lipid emulsion of MCT/vegetable oil (50:50) and another lipid emulsion of MCT/vegetable oil/fish oil (50:30:20) although more lipids have been supplied to the body per unit of time. The experimental results are given hereinafter in tables 6 and 7:

- 18 -

Table 6
Treatment A (Comparative Example 1)
 Free Fatty Acids in the Serum [$\mu\text{mol/l}$], MCT/vegetable oil (50:50)

Subject	after	Day 1	Day 2	Day 3
5 1.	0 h	0	22	39
	5 h	921	921	1068
2.	0 h	399	202	143
	5 h	996	742	762
3.	0 h	57	48	48
	5 h	1554	144	1408
4.	0 h	52	71	44
	5 h	1212	1173	979
5.	0 h	20	23	10
	5 h	903	1272	1405
10 6.	0 h	28	41	82
	5 h	1082	1271	1449
7.	0 h	97	90	122
	5 h	1068	949	1169
8.	0 h	27	47	34
	5 h	1219	1236	1140
Average \pm st.d.		85 \pm 122	68 \pm 55	65 \pm 43
		5 h	1119 \pm 198	1126 \pm 218
				1173 \pm 225

- 19 -

Table 7

Treatment B (according to the invention)Free Fatty Acids in the Serum [μ mol/l],

MCT/vegetable oil/fish oil (50:40:10)

5	Subject	after	Day 1	Day 2	Day 3	
1.		0 h	18	0	28	
		5 h	1321	1421	1102	
2.		0 h	298	254	431	
		5 h	1252	1101	1038	
3.		0 h	7	14	26	
		5 h	1363	1286	1239	
4.		0 h	25	8	7	
		5 h	1179	1197	1095	
10	5.	0 h	0	11	30	
		5 h	1165	1502	1381	
6.		0 h	4	0	19	
		5 h	1556	1295	1417	
7.		0 h	70	88	75	
		5 h	1053	983	963	
8.		0 h	0	12	0	
		5 h	1421	941	1012	
Average \pm st.d.		0 h	53 \pm 95	48 \pm 82	77 \pm 135	
		5 h	1289 \pm 150	1216 \pm 187	1156 \pm 160	

- 20 -

Table 8

Treatment C (Comparative Example 2)

Free Fatty Acids in the Serum [μ mol/l], MCT/vegetable oil/fish oil (50:30/20)

	Subject	after	Day 1	Day 2	Day 3
5	1.	0 h	13	12	0
		5 h	1051	828	863
10	2.	0 h	271	67	82
		5 h	900	816	899
15	3.	0 h	0	20	1
		5 h	1010	941	1006
	4.	0 h	32	136	128
		5 h	1175	1269	1229
	5.	0 h	0	10	0
		5 h	1139	1159	1024
	6.	0 h	15	34	21
		5 h	887	1252	1239
	7.	0 h	180	283	177
		5 h	1340	1335	1135
	8.	0 h	0	0	0
		5 h	873	811	852
Average \pm st.d.		0 h	64 \pm 97	70 \pm 90	51 \pm 65
		5 h	1047 \pm 154	1051 \pm 211	1031 \pm 146

15

3. Determination of Eicosapentaenic Acid (EPA, 20:5 n-3)
 Incorporation in Membrane Phospholipids of Platelets (Thrombocytes) and Leucocytes

20

The determination of the proportion of eicosapentaenic acid in the membrane phospholipids of the thrombocytes and leucocytes of

- 21 -

the eight subjects was performed by gas chromatography via the fatty acid methyl esters (percent by area method).

Table 9

5

Treatment B (according to the invention)
Eicosapentaenic acid in thrombocytes and leucocytes,
MCT/vegetable oil/fish oil (50:40:10)

	Day 1 (0 h)	Day 2 (0 h)	Day 3 (0 h)
EPA in thrombocytes	0.2 ± 0.1	0.7 ± 0.1	1.2 ± 0.1
Average ± st.d. (% by area)			
EPA in leucocytes	0.4 ± 0.1	0.7 ± 0.3	1.0 ± 0.3
Average ± st.d. (% by area)			

10

Table 10

Treatment C (Comparative Example 2)
Eicosapentaenic acid in thrombocytes and leucocytes,
MCT/vegetable oil/fish oil (50:30:20)

	Day 1 (0 h)	Day 2 (0 h)	Day 3 (0 h)
EPA in thrombocytes	0.4 ± 0.1	1.0 ± 0.1	1.7 ± 0.1
Average ± st.d. (% by area)			
EPA in leucocytes	0.4 ± 0.1	0.9 ± 0.1	1.4 ± 0.1
Average ± st.d. (% by area)			

15

A comparison of the results of table 9 with those of table 10 shows that in treatment C, for example, an EPA content of 0.9% by area was found in leucocytes on day 2. From the fish oil content in treatment B according to the invention being only half as high, an EPA content of 0.45% by area would be expected. Surprisingly, however, a significantly higher value was found, namely 0.7% by area. A similar result is obtained for day 3 as well as for thrombocytes on days 2 and 3.

20

30

Example 2 (in vitro)Apoprotein Uptake into the Emulsion Particles

5 Of great interest is the significantly lower enrichment (t-test, two-sided) of apoprotein C-I ($p < 0.0001$) and apoprotein C-III ($p < 0.0001$), which are both apoproteins that inhibit both, triglyceride hydrolysis and direct uptake of the emulsion particles into the target tissue (such as the liver), in the 10 emulsion particles having a composition according to the invention (preparation example 4) will presumably result in a more thorough intravascular scavenging of lipids than with the other lipid emulsion examined (preparation example 5).

15

Table 11

Uptake of Apoproteins C-I and C-III in Emulsion Particles,
(incubation: 3 h), MCT/vegetable oil/fish oil (50:40:10) vs.
MCT/vegetable oil/fish oil (50:30:20)

	MCT/vegetable oil/fish oil (50:40:10) (Preparative Example 4)	MCT/vegetable oil/fish oil (50:30:20) (Preparative Example 5)	
20	Apo C-I Uptake [μ g] Average \pm st.d.	5.1 ± 0.51 (n = 4)	23.4 ± 1.43 (n = 4)
25	Apo C-III Uptake [μ g] Average \pm st.d.	30.1 ± 2.67 (n = 4)	54.7 ± 4.00 (n = 4)

30 Lipid emulsions for parenteral administration will interact with endogeneous lipoproteins. During the infusion, the exogeneously supplied emulsion partly fuses with endogeneous LDL (low density lipoprotein; $d < 1.006$ g/ml), a lipoprotein with a high content of apoprotein B (apo B). Thus, the apo B enrichment in the fused emulsion particles is indicative of the extent of fusion of

- 23 -

exogeneously supplied emulsion with endogeneous LDL which has a relatively long plasma half life. Therefore, a high content of apo B in the fused emulsion particles must be considered indicative of prolonged residence time of the infused lipids.

5 Conversely, a low apo B content means a short plasma half life, corresponding to a reduced residence time in the plasma.

Two lipid emulsions according to preparative examples 4 and 5 were incubated with human LDL in lipoprotein-poor plasma at 37°C 10 for 4 hours, followed by a determination of the content of apoprotein B in the emulsion fraction.

Table 12

Apoprotein B Content in the Emulsion Particles,
15 MCT/vegetable oil/fish oil (50:40:10) vs.
MCT/vegetable oil/fish oil (50:30:20)

	MCT/vegetable oil/fish oil (50:40:10) (Preparative Example 4)	MCT/vegetable oil/fish oil (50:30:20) (Preparative Example 5)
Apo B Content [mg/dl]	0.05 ± 0.05 (n = 6)	0.27 ± 0.21 (n = 7)
Average ± st.d.		

20 The emulsion particles having a composition according to the invention show an apo B enrichment which is more than five times lower than that of the other lipid emulsion examined, corresponding to a higher hydrolysis rate. The difference is significant (t-test, two-sided; p < 0.05).

C L A I M S :

5 1. A lipid emulsion for parenteral administration comprising medium-chain triglycerides, at least one vegetable oil comprising triglycerides which supply omega-6-fatty acids, at least one fish oil comprising triglycerides which supply omega-3-fatty acids and conventional auxiliary agents and/or additives, characterized in that the lipid emulsion comprises, based on the total lipid content of the lipid emulsion:

10 - from 30% to 60% by weight of the medium-chain triglycerides;

15 - from 35% to 65% by weight of the vegetable oil(s) ;

 - from 5% to 20% by weight of the fish oil(s).

20 2. The lipid emulsion according to claim 1, characterized in that said medium-chain triglycerides are comprised of at least 90% of triglycerides of caprylic acid (C_8) and capric acid (C_{10}).

25 3. The lipid emulsion according to one or more of claims 1 or 2, characterized in that said vegetable oil is selected from safflower oil and/or soybean oil.

30 4. The lipid emulsion according to one or more of claims 1 to 3, characterized in that said fish oil is selected from sardine, salmon, herring, mackerel and/or other cold water fish oils or fish oils synthetically obtainable by re-esterification of glycerol with omega-3-fatty acids obtained by hydrolysis of cold water fish oil.

35 5. The lipid emulsion according to one or more of claims 1 to 4, characterized in that said fish oil contains at least 25% of eicosapentaenic acid in said triglycerides, based on the fatty acid methyl esters of the fish oil concentrate.

- 25 -

6. The lipid emulsion according to one or more of claims 1 to 5, characterized in that said fish oil contains at least 12% of docosahexaenic acid in said triglycerides, based on the fatty acid methyl esters of the fish oil concentrate.

5

7. The lipid emulsion according to one or more of claims 1 to 6, characterized in that the total lipid content is from 5% to 30% by weight, based on the emulsion.

10 8. Use of the lipid emulsion according to one or more of claims 1 to 7 for parenteral nutrition.

15 9. Use of the lipid emulsion according to one or more of claims 1 to 7 for parenteral administration with patients exhibiting exaggerated inflammatory reactions or with increased risk of vascular thrombosis or severe cardiac arrhythmia.

20 10. Use of the lipid emulsion according to one or more of claims 1 to 7 for parenteral administration with patients in post-operative or post-traumatic conditions or with inflammatory diseases.

AMENDED CLAIMS

[received by the International Bureau on 24 April 1997 (24.04.97);
original claims 1 and 8-10 amended; remaining claims unchanged (2 pages)]

5 1. An isotonic lipid emulsion for parenteral administration
 having a medium lipid droplet size of less than 1.0 μm
 comprising medium-chain triglycerides, at least one
 vegetable oil comprising triglycerides which supply omega-
 6-fatty acids, at least one fish oil comprising triglycer-
10 ides which supply omega-3-fatty acids and conventional
 auxiliary agents and/or additives, characterized in that
 the lipid emulsion comprises, based on the total lipid
 content of the lipid emulsion:
15 - from 30% to 60% by weight of the medium-chain
 triglycerides;
 - from 35% to 65% by weight of the vegetable oil(s) ;
 - from 5% to 20% by weight of the fish oil(s).

20 2. The lipid emulsion according to claim 1, characterized in
 that said medium-chain triglycerides are comprised of at
 least 90% of triglycerides of caprylic acid (C_8) and capric
 acid (C_{10}).

25 3. The lipid emulsion according to one or more of claims 1 or
 2, characterized in that said vegetable oil is selected
 from safflower oil and/or soybean oil.

30 4. The lipid emulsion according to one or more of claims 1 to
 3, characterized in that said fish oil is selected from
 sardine, salmon, herring, mackerel and/or other cold water
 fish oils or fish oils synthetically obtainable by re-
 esterification of glycerol with omega-3-fatty acids
 obtained by hydrolysis of cold water fish oil.

35 5. The lipid emulsion according to one or more of claims 1 to
 4, characterized in that said fish oil contains at least

25% of eicosapentaenoic acid in said triglycerides, based on the fatty acid methyl esters of the fish oil concentrate.

6. The lipid emulsion according to one or more of claims 1 to 5, characterized in that said fish oil contains at least 12% of docosahexaenoic acid in said triglycerides, based on the fatty acid methyl esters of the fish oil concentrate.

10 7. The lipid emulsion according to one or more of claims 1 to 6, characterized in that the total lipid content is from 5% to 30% by weight, based on the emulsion.

15 8. Use of the lipid emulsion according to one or more of claims 1 to 7 for the preparation of an emulsion for parenteral nutrition.

20 9. Use of the lipid emulsion according to one or more of claims 1 to 7 for the preparation of a medicament for the treatment of exaggerated inflammatory reactions, increased risk of vascular thrombosis or severe cardiac arrhythmia by parenteral administration.

25 10. Use of the lipid emulsion according to one or more of claims 1 to 7 for the preparation of a medicament for the treatment of post-operative or post-traumatic conditions or inflammatory diseases by parenteral administration.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/05184

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/19 A23L1/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 444 054 A (K.A.GARLEB ET AL.) 22 August 1995 see claims 14-19 see column 1, line 4-6 see column 19, line 40 - column 20, line 2 ---	1-7
X,P	US 5 470 839 A (P.LAUGHLIN ET AL.) 28 November 1995 see claims see column 3, line 15-19 see column 4, line 47 - column 5, line 17 ---	1-8
P,X	EP 0 687 418 A (CLINTEC NUTRITION) 20 December 1995 see claims see page 1, line 11-21 see page 1, line 55 - page 2, line 12 ---	1-10 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

3

Date of the actual completion of the international search

12 February 1997

Date of mailing of the international search report

26.02.97

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Van Moer, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 96/05184

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 311 091 A (B.BRAUN MELSUNGEN) 12 April 1989 cited in the application see claims; example 4 ---	1-7
A	DE 37 21 137 A (H.DIETL) 5 January 1989 cited in the application see claims 1-3,7-13; example 9 ---	1-10
A	FR 2 542 613 A (TERUMO) 21 September 1984 see claims & DE 34 09 793 A cited in the application -----	1-10

INTERNATIONAL SEARCH REPORT

In International application No.

PCT/EP 96/05184

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 9-10 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/05184

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-5444054	22-08-95	AU-A-	1884495	23-10-95
		CA-A-	2187628	12-10-95
		EP-A-	0754001	22-01-97
		WO-A-	9526646	12-10-95
US-A-5470839	28-11-95	AU-A-	2495095	18-01-96
		CA-A-	2153348	07-01-96
		EP-A-	0691079	10-01-96
		JP-A-	8067630	12-03-96
EP-A-687418	20-12-95	US-A-	5574065	12-11-96
		CA-A-	2147302	22-10-95
EP-A-311091	12-04-89	DE-A-	3734147	20-04-89
		DE-A-	3881815	22-07-93
		ES-T-	2058205	01-11-94
DE-A-3721137	05-01-89	DE-A-	3726299	23-02-89
FR-A-2542613	21-09-84	JP-C-	1783989	31-08-93
		JP-B-	3049890	31-07-91
		JP-A-	59172416	29-09-84
		BE-A-	899184	16-07-84
		DE-A-	3409793	20-09-84
		GB-A,B	2139889	21-11-84
		SE-A-	8401393	19-09-84
		US-A-	5034414	23-07-91